ZA200110053B - Factor via inhibitors. - Google Patents

Factor via inhibitors.

Info

Publication number
ZA200110053B
ZA200110053B ZA200110053A ZA200110053A ZA200110053B ZA 200110053 B ZA200110053 B ZA 200110053B ZA 200110053 A ZA200110053 A ZA 200110053A ZA 200110053 A ZA200110053 A ZA 200110053A ZA 200110053 B ZA200110053 B ZA 200110053B
Authority
ZA
South Africa
Prior art keywords
factor via
via inhibitors
inhibitors
factor
Prior art date
Application number
ZA200110053A
Other languages
English (en)
Inventor
Otmar Klingler
Manfred Schudok
Gerhard Zoller
Uwe Heinelt
Elisabeth Defossa
Hans Matter
Pavel Safar
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of ZA200110053B publication Critical patent/ZA200110053B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA200110053A 1999-06-08 2001-12-06 Factor via inhibitors. ZA200110053B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99111109A EP1059302A1 (en) 1999-06-08 1999-06-08 Factor VIIa inhibitors

Publications (1)

Publication Number Publication Date
ZA200110053B true ZA200110053B (en) 2002-07-03

Family

ID=8238315

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200110053A ZA200110053B (en) 1999-06-08 2001-12-06 Factor via inhibitors.

Country Status (32)

Country Link
US (1) US6500803B1 (cs)
EP (2) EP1059302A1 (cs)
JP (1) JP4546683B2 (cs)
KR (1) KR100979069B1 (cs)
CN (1) CN1359390B (cs)
AR (1) AR024292A1 (cs)
AT (1) ATE246707T1 (cs)
AU (1) AU774037B2 (cs)
BR (1) BR0011461A (cs)
CA (1) CA2376064C (cs)
CZ (1) CZ300365B6 (cs)
DE (1) DE60004363T2 (cs)
DK (1) DK1189929T3 (cs)
EE (1) EE04855B1 (cs)
ES (1) ES2202137T3 (cs)
HK (1) HK1047289B (cs)
HR (1) HRP20010912B1 (cs)
HU (1) HUP0201451A3 (cs)
IL (2) IL146731A0 (cs)
ME (1) MEP57708A (cs)
MX (1) MXPA01012568A (cs)
NO (1) NO328249B1 (cs)
NZ (1) NZ515966A (cs)
PL (1) PL202879B1 (cs)
PT (1) PT1189929E (cs)
RS (1) RS50415B (cs)
RU (1) RU2248359C2 (cs)
SI (1) SI1189929T1 (cs)
SK (1) SK286902B6 (cs)
TR (1) TR200103550T2 (cs)
WO (1) WO2000075172A2 (cs)
ZA (1) ZA200110053B (cs)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1059302A1 (en) * 1999-06-08 2000-12-13 Aventis Pharma Deutschland GmbH Factor VIIa inhibitors
DE10005631A1 (de) * 2000-02-09 2001-08-23 Max Planck Gesellschaft Arginin-Mimetika als Faktor X¶a¶-Inhibitoren
GB0014134D0 (en) * 2000-06-10 2000-08-02 Astrazeneca Ab Combination therapy
EP1364960A4 (en) * 2001-02-02 2005-05-18 Chugai Pharmaceutical Co Ltd PEPTIDE DERIVATIVES
GB0127615D0 (en) * 2001-07-09 2002-01-09 Aventis Pharm Prod Inc Substituted amides, sulfonamides and ureas useful for inhibiting kinase activity
WO2005016901A1 (en) 2003-08-18 2005-02-24 H. Lundbeck A/S Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
TWI453198B (zh) 2005-02-16 2014-09-21 Lundbeck & Co As H 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s）-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法
TWI376373B (en) 2005-02-16 2012-11-11 Lundbeck & Co As H Crystalline base of a pharmaceutical compound
ATE455103T1 (de) * 2005-06-24 2010-01-15 Bristol Myers Squibb Co Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
US20080070987A1 (en) * 2006-05-12 2008-03-20 Francesc Yraola Font Meta-xylylenediamine vanadate salts
CN116655730A (zh) 2016-06-01 2023-08-29 雅斯娜 用于治疗多种疾病的n-己酸-l-酪氨酸-l-异亮氨酸-(6)-氨基己酰胺的衍生物
EP4491193A3 (en) 2019-07-01 2025-04-30 Tonix Pharma Limited Anti-cd154 antibodies and uses thereof
MX2023008055A (es) 2021-01-06 2023-08-22 Tonix Pharma Ltd Métodos para inducir tolerancia inmune con anticuerpos anti-cd154 modificados.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023236A (en) * 1988-04-07 1991-06-11 Corvas, Inc. Factor VII/VIIA active site inhibitors
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
DE4115468A1 (de) * 1991-05-11 1992-11-12 Behringwerke Ag Amidinophenylalaninderivate, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel als antikoagulantien
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
JP3655632B2 (ja) * 1994-04-26 2005-06-02 アベンティス・ファーマスーティカルズ・インコーポレイテッド 第Ｘａ因子インヒビター
EP0892780B1 (en) * 1996-02-22 2002-11-20 Bristol-Myers Squibb Pharma Company M-AMIDINO PHENYL ANALOGS AS FACTOR Xa INHIBITORS
AR013084A1 (es) * 1997-06-19 2000-12-13 Astrazeneca Ab Derivados de amidino utiles como inhibidores de la trombina, composicion farmaceutica, utilizacion de dichos compuestos para la preparacion demedicamentos y proceso para la preparacion de los compuestos mencionados
EP0987274A1 (en) * 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors
EP1059302A1 (en) * 1999-06-08 2000-12-13 Aventis Pharma Deutschland GmbH Factor VIIa inhibitors

Also Published As

Publication number Publication date
HRP20010912B1 (en) 2010-10-31
EE200100662A (et) 2003-04-15
MEP57708A (en) 2011-05-10
SK286902B6 (sk) 2009-07-06
MXPA01012568A (es) 2002-04-10
NO20016005L (no) 2002-02-06
EP1059302A1 (en) 2000-12-13
BR0011461A (pt) 2002-03-19
HK1047289A1 (zh) 2003-02-14
SK17592001A3 (sk) 2002-05-09
PL202879B1 (pl) 2009-07-31
HUP0201451A3 (en) 2003-08-28
ATE246707T1 (de) 2003-08-15
IL146731A (en) 2007-07-24
JP2003502294A (ja) 2003-01-21
SI1189929T1 (en) 2004-02-29
NO328249B1 (no) 2010-01-18
US6500803B1 (en) 2002-12-31
CZ20014357A3 (cs) 2002-03-13
EE04855B1 (et) 2007-06-15
DE60004363T2 (de) 2004-06-24
PL352200A1 (en) 2003-08-11
TR200103550T2 (tr) 2002-05-21
YU86101A (sh) 2004-07-15
WO2000075172A2 (en) 2000-12-14
CA2376064C (en) 2011-04-26
EP1189929A2 (en) 2002-03-27
PT1189929E (pt) 2003-12-31
IL146731A0 (en) 2002-07-25
DK1189929T3 (da) 2003-11-24
WO2000075172A3 (en) 2001-05-31
HRP20010912A2 (en) 2003-04-30
NZ515966A (en) 2003-09-26
RU2248359C2 (ru) 2005-03-20
CN1359390B (zh) 2010-05-26
AU774037B2 (en) 2004-06-17
RS50415B (sr) 2009-12-31
AR024292A1 (es) 2002-09-25
CZ300365B6 (cs) 2009-04-29
DE60004363D1 (de) 2003-09-11
KR20020020728A (ko) 2002-03-15
HK1047289B (zh) 2010-10-22
HUP0201451A2 (en) 2002-08-28
AU5397600A (en) 2000-12-28
ES2202137T3 (es) 2004-04-01
KR100979069B1 (ko) 2010-08-31
NO20016005D0 (no) 2001-12-07
CA2376064A1 (en) 2000-12-14
CN1359390A (zh) 2002-07-17
JP4546683B2 (ja) 2010-09-15
EP1189929B1 (en) 2003-08-06

Similar Documents

Publication Publication Date Title
GB9900416D0 (en) Inhibitors
ZA200109890B (en) Metalloprotease inhibitors.
MXPA01013362A (es) Anticuerpos de humano, anti-alfavbeta3 recombinantes, °cidos nucleicos que codifican a los mismos y metodos de uso.
ZA200000894B (en) 4-Phenyl-pyridine derivatives.
ZA200201055B (en) Amino-triazolopyridine derivatives.
ZA200200477B (en) 2-pyrazolin-5-ones.
EG24361A (en) 4-pyrimiding1-n-acy1.l.phenlalanines
ZA200108735B (en) Renin inhibitors.
ZA200108016B (en) Pyrazolobenzodiazephines as CDK2 inhibitors.
ZA200202537B (en) Pour-on-formulations.
ZA200109595B (en) 13-methyl-erythromycin derivatives.
ZA200201829B (en) New phenylpiperazines.
ZA200203762B (en) 4-pyridinyl-IN-acyl-L-phenylalanines.
ZA200108968B (en) New compounds.
ZA200110053B (en) Factor via inhibitors.
EP1153022A4 (en) PROTEASE INHIBITORS
ZA200007405B (en) Angiogenesis inhibitors.
ZA200201276B (en) 3-Amino-2-phenyl-propane derivatives.
MXPA02000261A (es) Aminoindanos novedosos.
MXPA01011285A (es) Derivados de tio-oxindol.
GB2389113B (en) B-secretase inhibitor
GB0029720D0 (en) I.S machine7544232001
ZA200204581B (en) Nitro-sulfobenzamides.
ZA200005361B (en) Positioning arrangement.
ZA200001460B (en) Support.